Close Menu

NEW YORK – Cancer centers and health systems in the US continue to invest in molecular testing, decision support, and other tools for personalizing treatment, but have yet to establish clear metrics for evaluating the extent to which these approaches are benefitting patients, according to a recent survey.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Dec
02
Sponsored by
Qiagen

The Phosphoinositide 3-Kinase (PI3K) pathway is one of the most frequently altered pathways in human cancer and plays a significant role in disease progression and resistance to endocrine therapy.